Milan, Italy, September 19, 2024, 7 am CET Newron presents H1 2024 results and provides business update
Milan, Italy, May 13, 2024, 07:00 am CET Newron reports compelling additional data documenting the efficacy of evenamide in pivotal study 008A in poorly responding schizophrenia patients
Milan, Italy, April 30, 2024, 07:00 am CET Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients
Milan, Italy, April 17, 2024, 11:30 am CET Newron announces AGM 2024 results
Milan, Italy, March 19, 2024, 07:00 am CET Newron presents 2023 financial results and provides 2024 outlook
Milan, Italy, March 15, 2024, 07:00 am CET Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement
Milan, Italy, March 14, 2024, 17:45 CET Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares
Milan, Italy, January 04, 2024, 7am CET Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia (TRS)
Milan, Italy, December 29, 2023, 07:00 am CET Newron completes enrollment of schizophrenia patients in potentially pivotal study 008A with Evenamide
Milan, Italy, October 9, 2023, 12:45 pm CEST Newron TRS study 6 months’ results: Evenamide substantially improves patients to an extent that they no longer meet protocol entry criteria
Milan, Italy, August 4, 2023, 7 am CEST Newron announces H1 2023 results and provides R&D update
Milan, Italy, May 2, 2023, 7 am CEST Newron announces Senior Management Team changes
March 20, 2023, 07:00 am CEST Newron reports compelling topline results from all patients in Study 014, its Phase II clinical trial evaluating evenamide as add-on therapy for treatment-resistant schizophrenia
March 14, 2023, 07:00 am CEST Newron announces 2022 financial results and provides outlook for 2023
February 16, 2023, 07:00 am CEST Newron reports striking one-year interim efficacy results from its Phase II clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia
January 3, 2023, 7am CEST Newron announces striking six-month interim results from its exploratory clinical trial evaluating evenamide as add-on therapy for patients with treatment resistant schizophrenia
September 15, 2022, 7 am CET Newron provides H1 2022 results and updates on R&D and business activities
June 7 2022, 7am CEST Newron presents encouraging interim results for evenamide in patients with Treatment-Resistant Schizophrenia (TRS) at the 33rd CINP Hybrid World Congress of Neuropsychopharmacology
March 15 2022, 7am CEST Newron announces 2021 financial results and provides outlook for 2022
December 1 2021, 5:45pm CEST Change in Newron Board of Directors
October 18 2021, 5:45pm CEST Newron receives fifth tranche from financing agreement with European Investment Bank (EIB)
September 6 2021, 5:45pm CEST Newron receives fourth tranche from financing agreement with European Investment Bank (EIB)
September 6 2021, 7am CEST Newron initiates first potentially pivotal study with evenamide in patients with schizophrenia
May 20 2021, 7am CEST Newron announces Paragraph IV ANDA filings for Xadago® (safinamide) in the USA
May 04 2021, 7am CEST Newron announces Paragraph IV ANDA filing for Xadago® (safinamide) in the USA
Apr 01 2021, 7am CEST Newron announces results of explanatory studies with evenamide in healthy volunteers and patients with schizophrenia
March 16 2021, 7am CEST Newron announces 2020 financial results and provides outlook for 2021
Mar 15 2021, 7am CEST Newron and Zambon sign agreement for potentially pivotal study with safinamide in Parkinson’s disease patients
Sep 15 2020, 7am CEST: Newron announces half-year 2020 results
Aug 11 2020, 7am CEST Newron Pharmaceuticals provides clinical and business update
May 04 2020, 7am CEST Newron Reports Top-Line Results from its STARS Study Evaluating Sarizotan in Patients with Rett Syndrome
Mar 31 2020, 5:45pm CEST Newron AGM Result and Clinical and Business Update
Mar 05 2020, 7am CEST Newron announces 2019 financial results and provides outlook for 2020
Jan 09 2020, 7am CEST Newron announces initiation of new clinical trial with Evenamide in patients with schizophrenia, following approval of plan by FDA
Dec 09 2019, 5:45pm CEST Newron Pharmaceuticals to Request Type A FDA Meeting Prior to Unblinding of STARS Clinical Trial Data